Fish oil may help cancer drugs work better in esophageal cancer trial

NCT ID NCT07272382

Recruiting now Disease control Sponsor: Fudan University Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether adding omega-3 fatty acids (EPA and DHA) to standard PD-1 inhibitor therapy helps patients with advanced esophageal cancer. About 142 adults will receive either omega-3 or placebo drops daily for 6 months alongside their cancer treatment. The main goal is to see if omega-3 helps maintain muscle mass and improves overall outcomes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Omega-3 fatty acids (EPA and DHA) as oral drops
What this could lead to: If it works, adding omega-3 could help patients with advanced esophageal cancer maintain muscle mass and possibly improve how well PD-1 therapy works.
What could go wrong: This is a small, early-phase trial (142 people) testing a dietary supplement, so results may not be conclusive. The benefit may be modest or not appear at all.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ESOPHAGEAL NEOPLASMS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

esophageal cancer Esophageal Neoplasms neoplasm of esophagus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ESOPHAGEAL NEOPLASMS

Contacts and locations

Locations

Fudan University Shanghai Cancer Center
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.